drugset / Trial / NCT00809354

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

NCT00809354

Phase 3 Terminated 2720 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the long-term analgesic efficacy and safety of tanezumab for patients with osteoarthritis (OA) of the knee or hip currently experiencing partial benefit from, and are tolerating, non-steroidal anti-inflammatory drug (NSAID) therapy.

Timeline

Start
2009-02-12
Primary completion
2010-10-28
Completion
2011-01-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 100 mg Oral
Subject Naproxen Small molecule 500 mg Oral
Subject Tanezumab Monoclonal antibody 5 mg Intravenous
Subject Tanezumab Monoclonal antibody 10 mg Intravenous

Indications